PDA Webinar: Regulatory Challenges, Perspectives, and Convergence to Progress ATMPs

Online
Ask a Question

We’re proud to welcome Peter W. Marks, MD, PhD, Director, CBER, U.S. FDA, who is joining us for this final webinar in 2020 PDA Advanced Therapy Medicinal Products Month Webinar Series!

As more and more companies are transitioning into cell and gene manufacturing, it is imperative that regulatory requirements allow for an acceptable risk-based approach that can be applied across manufacturing sites.

This webinar will highlight global regulatory challenges, current regulatory thinking, and efforts that are being proposed and/or undertaken to promote convergence in global regulatory approaches for cell and gene therapy manufacturing.

In addition to the presentation by Dr. Marks, we will be hearing an industry perspective on lessons learned from an RMAT designation request.

Following the presentations, get your questions answered during a live 30-minute Q&A session with the speakers.

This webinar is presented as part of the 2020 PDA Advanced Therapy Medicinal Products Month.

Standard Pricing

Standard Member Price

$200

GovernmentMember Only

$200

Health AuthorityMember Only

$200

AcademicMember Only

$200

Non-Member

$200

See Qualifying Criteria for Member Types.

Day 1

11:00 a.m. – 11:30 a.m.
Moving Toward Global Regulatory Convergence for Advanced Therapy Medicinal Products
Peter W. Marks, MD, PhD, Director, CBER, U.S. FDA

11:30 a.m. – 12:00 p.m.
Lesson Learned from an RMAT Designation Request
Stephen P. Westover, Director of Regulatory Affairs, Cook Myosite Incorporated

12:00 p.m. – 12:30 p.m.
Q&A with Speakers

Agenda is subject to change.

PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.